Observational, Bi-directional (Prospective and Retrospective) Study for Patients With Newly Diagnosed Ovarian Cancer Stages IA to IVB, or Persistent or Recurrent Disease From January 2021; Irrespective of Histology

Study acronym: OLIVIA
StatusActive, Not Recruiting
PhaseNot specified
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 2 years 2 months later Jun 30, 2027 → Sep 29, 2029
See other at-risk trials from AstraZeneca

Record History

See every version on ClinicalTrials.gov ↗

  1. Enrollment closed, study ongoing Show 4 more changesShow less
    • Enrollment target: estimated 250 to confirmed 256
    • Study sites: 15 to 14
    • Eligibility criteria expanded, about 6 words
    • Secondary endpoints: details revised at 3 of 3 entries
  2. Primary and study completion pushed from Jun 30, 2027 to Sep 29, 2029v10
  3. Trial sites reduced: 18 → 15 locationsv9
  4. Trial sites expanded: 13 → 18 locationsv8
  5. Trial sites expanded: 1 → 13 locationsv7
  6. Primary and study completion pushed from Mar 31, 2026 to Jun 30, 2027v6
  7. 3 versions Re-verified since Dec 19, 2025, no change to tracked fieldsv3-v5
  8. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 1
    • Start date changed from estimate of Sep 30, 2025 to Sep 19, 2025
    v2
  9. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
AstraZeneca
734 trials monitored
See 61 trials at risk
Ovarian Cancer
1,347 trials monitored
See 96 trials at risk
The findings from this study have the potential to serve as a foundation for evaluating the current practices related to surgical procedures, systemic therapies, hyperthermic intraperitoneal chemotherapy, and referrals to geneticists for OC patients. By identifying the strengths and weaknesses of the existing care, this project intends to generate valuable insights that can lead to the implementation of quality parameters for the treatment of ovarian cancer in the country.
Trial Details
NCT Number NCT07167433
Lead Sponsor AstraZeneca
Conditions
(from sponsor)		 Ovarian Cancer
Related terms Ovarian Neoplasms
Enrollment 256 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov